Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Crizotinib	TA296 - Critzotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cyclophosphamide injection		For hospital use only
Cyclophosphamide tablets		For oncology
Cytarabine injection		Funding approval should be sought before initiation
Cytarabine liposomal injection		For hospital use only
Cytarabine–daunorubicin liposomal (Vyxeos®)	TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran capsules		Use following hip and knee surgery – full course of treatment supplied on discharge
Dabrafenib	TA321 - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dacarbazine injection		For hospital use only
Daclizumab concentrate for infusion	TA441 - Daclizumab for treating relapsing–remitting multiple sclerosis	For Hospital Use Only. Please see drug safety alert. Safety alert

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.